Core Viewpoint - The research led by Professor Zhang Rongzhen's team has successfully developed an efficient in vitro enzyme-catalyzed system for high-level bilirubin biosynthesis, achieving a yield of 1.7 g/L and a conversion rate of 95.8%, laying a solid foundation for industrial production [2][4]. Group 1: Enzyme Optimization - The study clarified the classical two-enzyme catalytic pathway from heme to bilirubin and identified the most efficient enzyme combinations through systematic evolutionary analysis [4]. - The combination of rat HO-1 and its specific cytochrome P450 reductase (CPR) showed the highest efficiency in converting heme to biliverdin, while the rat BVR-A subtype performed best in reducing biliverdin to bilirubin [4]. - Structural analysis of key enzymes led to the development of soluble truncated variants RnCPRΔ54 and RnHO-1Δ22, which maintained substrate affinity and catalytic efficiency while improving solubility [4][5]. Group 2: Addressing Inhibitory Factors - Initial one-pot reactions showed a heme conversion rate of 83.9%, but bilirubin yield was only 48.1%, indicating material loss due to bottlenecks in the first step of heme oxygenase catalysis [5]. - The study identified Fe²⁺ as a negative factor affecting product stability, as it formed complexes with deprotonated biliverdin or bilirubin, leading to degradation [7]. - The researchers developed a dual strategy to stabilize the reaction, using HEDP to chelate Fe²⁺ and lowering the reaction pH to suppress deprotonation, which together increased bilirubin yield to 80.1% [7][8]. Group 3: Integrated Multi-Enzyme System - The research revealed carbon monoxide (CO) as another inhibitory factor, as it formed stable complexes with heme, obstructing substrate binding and enzyme activity [8]. - To eliminate all inhibitory factors, the team constructed a fully integrated multi-enzyme system, incorporating a CO dehydrogenase and a formate dehydrogenase for in situ NADPH regeneration [8]. - This integrated system successfully converted 3 mM of heme to 2.87 mM of bilirubin in a 1-liter reaction, achieving a yield of 95.8%, confirmed as the bioactive bilirubin IXα isomer [8].

关键词 | 资本事件 |深势科技 【SynBioCon】 获 悉，近日，AI for Science（人工智能驱动的科学研究）领域的标杆企业 深势 科技 宣布完成总额 超 8 亿元人民币的 C 轮融资 。这份出资方名单颇具份量：达晨财智、京国瑞基 金、北京市人工智能产业投资基金、北京市医药健康产业投资基金、联想创投、元禾璞华等机构共同 押注。 这并非简单的资金输送，而是一次凝结了国有资本意志、产业资本眼光与财务资本信心的战略合围。 它释放的信号十分明确：AI for Science 已不再只是前沿交叉学科的概念叙事，而是被主流资本市 场以更系统、更确定的方式纳入战略配置的投资主线；而深势科技，正处在这一浪潮的关键枢纽位 置。 意义远超金额本身 这次 融资被定义为深势科技发展历程中的「重要里程碑」，其意义远超过金额本身。它发生在全球 AI for Science 进入规模化应用「快车道」的宏观背景下，是资本市场用真金白银对一家中国科技 公司技术路径、商业化潜能及长期统治力的集中投票。在资本趋于谨慎的周期中，这种体量的多方联 合注资等同于一次「强信号」释放：不仅为赛道带来明显的信心增量，也迫使市场用更现实的视角重 ...

Core Viewpoint - Liaoning Jinfa is expanding its production capacity by renovating its lactic acid production line and constructing a new 100,000-ton bio-based succinic acid production line, which is expected to significantly enhance its bio-based materials segment [1][3]. Project Overview - The project will utilize a "reconstruction + new construction" model, converting existing lactic acid production facilities to produce 50,000 tons of succinic acid annually, while also building a new fermentation workshop and a purification workshop for an additional 50,000 tons of succinic acid [2]. - Upon completion, the total production capacity for bio-based succinic acid will increase from 50,000 tons/year to 150,000 tons/year, serving as a crucial capacity support for the company's bio-based monomer segment [3]. - The project is part of a larger integrated bio-based materials initiative in the Panjin Liaobin Coastal Economic and Technological Development Zone, which includes a total investment of 7.89 billion yuan [4][5]. Production Capacity and Investment - The project will cover an area of 1,450 acres, with a planned total investment of 7.89 billion yuan, divided into three phases [5]. - The first phase will occupy 740 acres with an investment of 1 billion yuan, originally intended for the production of 10,000 tons of bio-based 1,4-butanediol, 50,000 tons of lactic acid, and 5,000 tons of halogen-free green flame retardants [6]. Industry Positioning - Jinfa Technology has established a complete "bio-based monomer-polymer-modification" industrial chain [7]. - The company has achieved stable production of 50,000 tons of bio-based succinic acid and 10,000 tons of bio-based BDO, with bio-based succinic acid produced through microbial fermentation achieving 100% bio-based carbon content [9]. Financial Performance - In the first three quarters of 2025, the company reported revenue of 49.616 billion yuan, a year-on-year increase of 22.62%, and a net profit of 1.065 billion yuan, up 55.86% [15]. - The stock price increased from 8.12 yuan at the beginning of the year to 18.45 yuan by December 24, 2025, reflecting a 127.2% increase, significantly outperforming the market [16]. Innovation and New Developments - Jinfa Technology has made significant technological breakthroughs, including the launch of a new generation of bio-based LCP materials, becoming the first domestic supplier to achieve ISCC PLUS certification for LCP materials [10]. - The company is also expanding into new fields, having established a new subsidiary focused on bio-based materials technology research and development [13].

Core Insights - The article discusses Shanghai's action plan for accelerating food technology innovation from 2026 to 2030, aiming to enhance the food industry's development through synthetic biology and digital manufacturing [1][2]. Group 1: Goals and Objectives - By 2027, the plan aims to achieve significant breakthroughs in synthetic biology food creation, including the development and approval of 3-5 new food raw materials, additives, and related products, as well as 1-2 special medical purpose formula foods [2]. - The initiative seeks to cultivate over 5 innovative enterprises with core food creation technologies and digital manufacturing capabilities, and establish a comprehensive standard system for food industry development [2]. Group 2: Long-term Vision - By 2030, the goal is to create a globally influential hub for food technology innovation, resulting in a safer, healthier, more convenient, and sustainable food innovation ecosystem [3]. - The plan includes forming an innovation enterprise cluster covering the entire food industry chain, nurturing 8-10 leading companies in specific segments, and promoting 1-2 synthetic biology food innovation companies to go public [3]. - The food industry output value is projected to exceed 150 billion yuan, alongside the establishment of a national-level nutrition and health industry cluster and new food pilot parks [3]. Group 3: Research and Development Focus - The plan emphasizes accelerating the exploration of new food raw materials, focusing on functional proteins, carbohydrates, and lipids, while also considering active substances, flavors, and colorants [5]. - It aims to enhance biosynthesis technology through the integration of synthetic biology and artificial intelligence, improving the performance and adaptability of standardized components and chassis cells [5]. - Support for the development of new food products includes alternative proteins, plant-based meats, 3D-printed foods, and other innovative food solutions to meet diverse consumer needs and sustainable development goals [5].

Core Viewpoint - The article highlights the participation of Suzhou Juwei Yuanchuang Biotechnology Co., Ltd. in the fourth New Leaf Award, focusing on their innovative products in the bio-based sector, including bio-based 1,4-diaminobutane, fully bio-based packaging materials, and straw-derived glucose [2][3]. Group 1: New Leaf Award - The New Leaf Award is a global, comprehensive award dedicated to innovation in the bio-based field, often referred to as the "Oscar" of the bio-based industry [2]. - The fourth New Leaf Award ceremony will take place during the 11th Bio-based Conference and Exhibition in 2026 [2]. Group 2: Participating Company and Products - Suzhou Juwei Yuanchuang focuses on straw-based bio-manufacturing and is competing for three awards: "Innovative Materials Award," "Innovative Applications Award," and "Most Commercially Valuable Award" [3][4]. - The company has entered the DT New Materials global bio-based and bio-manufacturing industry service platform [3]. Group 3: Award Categories - The four award categories include: Innovative Materials Award, Innovative Applications Award, Most Commercially Valuable Award, and Innovative Industry Solutions Award [4]. Group 4: Product Innovations - **Bio-based 1,4-diaminobutane**: This product is a core monomer for high-temperature nylon, synthesized from straw using proprietary technology, overcoming the reliance on petrochemical or food sources, and significantly reducing production costs [15][8]. - **Fully Bio-based Packaging Materials**: Developed using agricultural by-products, these materials are 100% bio-based and fully biodegradable, addressing both high-value utilization of straw and the greening of packaging materials [10][16]. - **Straw-derived Glucose**: This glucose is produced from straw and offers over 40% carbon reduction compared to traditional glucose sources, providing a stable and economical green raw material for bio-manufacturing [12][17]. Group 5: Market and Production - The company has completed the construction of a large-scale production base and has established application collaborations with leading industry players, indicating strong market competitiveness [15]. - The glucose product has undergone extensive testing with positive feedback from hundreds of universities, research institutions, and enterprises, demonstrating its market acceptance and scalability [17].

Core Viewpoint - The article highlights a significant breakthrough in the biosynthesis of medium-chain fatty acids (MCFAs) by a research team led by Professor Wang Dan from Chongqing University, utilizing engineered Escherichia coli and bamboo waste as a substrate, achieving a production yield of 9.05 g/L in a 5 L fermentation tank [2][5]. Group 1: Research Breakthroughs - The research team constructed an efficient synthesis pathway in E. coli by deleting specific genes to block β-oxidation and enhance the utilization of multiple carbon sources, resulting in an initial MCFA yield of 2.29 g/L [4]. - Further enhancements were made using protein engineering techniques, achieving a yield of 5.83 g/L and the first synthesis of C6 fatty acids [4]. - The introduction of a carbonic anhydrase gene from Anabaena sp. 7120 improved CO₂ conversion efficiency, raising the yield to 6.72 g/L, and subsequent overexpression of a fatty acid regulatory factor led to a final yield of 9.05 g/L [5]. Group 2: Economic and Environmental Impact - The economic analysis indicates that using bamboo waste hydrolysate instead of glucose as a carbon source reduces the production cost of MCFAs by approximately 17% per ton, showcasing both economic and environmental advantages of this biosynthetic route [5]. Group 3: Institutional Background - Chongqing University is a key national research university, actively contributing to regional and industrial development, with significant achievements in research funding and project approvals [7][8]. - The university's chemical engineering and technology programs rank highly globally, reflecting its strong academic capabilities and commitment to innovation in fields like bio-manufacturing [8]. Group 4: Research Team and Leadership - Professor Wang Dan leads the research team, focusing on biosynthesis of chemical products and new materials, with numerous publications in high-impact journals and significant contributions to national research projects [9].

Core Viewpoint - The non-grain raw material synthetic biological manufacturing industry in China has made significant progress, with partial industrialization in areas such as bio-based plastics, fibers, and rubber, driven by independent research and development and supportive government policies [2][5]. Group 1: Industry Development - The industry has seen increased capital attention, with local governments enhancing financial support, such as the establishment of a 5 billion yuan fund in Changde City for technology research and project implementation [2]. - The recent Fifth Biomass High-Value Utilization Forum in Hangzhou served as a crucial platform for promoting technological innovation and industry integration [2]. - The development of bio-based composite materials from straw is highlighted as a key opportunity to tap into a trillion-level market for bio-based new materials [2][5]. Group 2: Motivations for Development - Traditional biological manufacturing relies on food crops like corn and glucose, which can lead to conflicts over food and land resources. Utilizing approximately 900 million tons of straw produced annually in China can alleviate these issues while providing sustainable raw materials for large-scale production [6]. - The chemical industry’s heavy reliance on non-renewable resources like oil is becoming unsustainable. Non-grain raw material biological manufacturing can reduce this dependency and ensure a stable supply of raw materials for the green materials industry [6]. Group 3: Strategic Timing and Policy Support - The "14th Five-Year Plan" and "15th Five-Year Plan" emphasize biological manufacturing as a key economic growth point, with a target to increase the non-grain raw material proportion from less than 5% to 30% by 2030 [7]. - Continuous policy support from the State Council and relevant ministries aims to cultivate potential sectors like biological manufacturing, reinforcing the strategic direction for industry development [7]. - The current period is identified as a golden development phase for biological manufacturing, driven by national strategy, addressing food security concerns, and facilitating low-carbon industrial transformation [7].

Core Viewpoint - The article discusses the technological transformation and intelligent upgrade project of Hubei Meiqi Health Technology Co., Ltd.'s functional health food production line, highlighting its investment and production capacity [1]. Project Basic Information - Project Name: Technological transformation and intelligent upgrade of the functional health food production line at Hubei Meiqi Health Technology Co., Ltd. [2] - Construction Unit: Hubei Meiqi Health Technology Co., Ltd. [2] - Location: 189 Xiaoting Avenue, Xiaoting District, Yichang City, Hubei Province [2] - Nature: Expansion and renovation [2] - Project Investment: 43.77 million yuan [2] - Construction Period: 2 months [2] - Construction Content: The project will produce MQ001 fermentation powder (annual output of 240 tons), MQ003 fermentation powder (annual output of 64 tons), MQ004 fermentation liquid (annual output of 3000 tons), MQ005 fermentation liquid (annual output of 3200 tons), and MQ009 (annual output of 16 tons) [2]. Company Overview - Hubei Meiqi Health Technology Co., Ltd. was established in December 2021, jointly invested by Hubei Angel Yeast Group Co., Ltd., Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., and Zhejiang Huinda Biotechnology Co., Ltd. [3] - The company is headquartered in Yichang City, Hubei Province, focusing on the research, production, and sales of nutritional health food raw materials and personal care functional raw materials in the industrial microbiology field [3].

Core Viewpoint - The article discusses the advancements in Sustainable Aviation Fuel (SAF) technology, particularly focusing on Junheng Biotechnology's innovative approach to converting waste cooking oil into clean aviation fuel, addressing the challenges of traditional methods and highlighting the potential for significant carbon emissions reduction in the aviation industry by 2050 [2][3]. Group 1: SAF Market and Technology Overview - The global aviation industry is projected to emit over 2 billion tons of carbon annually by 2050, with SAF technology expected to contribute 65% of the necessary emissions reductions to achieve carbon neutrality [2]. - Junheng Biotechnology has delivered over 300,000 tons of SAF to the international market and is constructing the world's largest SAF production facility, capable of processing 1 million tons of waste oil annually [3][25]. - The HEFA (Hydroprocessed Esters and Fatty Acids) technology is identified as the most commercially viable route for SAF production, expected to dominate the Chinese SAF market by 2030 [7][25]. Group 2: Challenges in SAF Production - Traditional SAF production methods face significant challenges due to the complex composition of waste oils, which contain various contaminants that can damage catalysts [10][12]. - The stringent requirements for feedstock purity in conventional methods lead to high costs and environmental concerns due to waste generation from extensive pre-treatment processes [16][20]. Group 3: Junheng's Innovative Approach - Junheng's strategy simplifies the pre-treatment process by allowing waste cooking oil to undergo only basic washing before entering the hydrogenation unit, significantly reducing investment costs and environmental impact [19][20]. - The company has developed a robust catalyst capable of withstanding high levels of contaminants, enabling efficient conversion of waste oils into SAF without extensive pre-treatment [21][23]. Group 4: Comparative Analysis of SAF Technologies - Other SAF production technologies, such as AtJ (Alcohol-to-Jet) and G-FT (Gasification-Fischer Tropsch), face their own challenges, including high raw material costs and technical issues like tar formation [28][34]. - PtL (Power-to-Liquid) technology, while theoretically capable of high emissions reductions, currently suffers from low energy efficiency and high production costs, making it less competitive without policy support [39][43]. Group 5: Future of China's SAF Industry - The Chinese SAF industry is still in its pilot phase, with a lack of comprehensive policy frameworks compared to the EU's established blending mandates [48][50]. - Junheng's advancements demonstrate that technological innovation can lower costs and enhance competitiveness in the SAF sector, with expectations for HEFA technology to lead in the short term while G-FT may gain traction in the medium term [51][53].

Core Viewpoint - During the "14th Five-Year Plan" period, China's bio-manufacturing industry has experienced significant growth, becoming a crucial force for optimizing and upgrading the economic structure, with a total scale reaching 1.1 trillion yuan [2][3]. Industry Overview - The bio-manufacturing industry in China has steadily expanded, achieving a total scale of 1.1 trillion yuan, with bio-fermentation products accounting for over 70% of global production [3][4]. - The annual output value of sub-sectors such as food additives and biopharmaceuticals exceeds 400 billion yuan, establishing bio-manufacturing as a new economic growth point [3][4]. Technological Innovation - China's bio-manufacturing sector holds over 20% of global patent applications, with the establishment of several national key laboratories and industrial innovation platforms [4]. - New instruments such as domestic high-throughput gene sequencers and large-scale fermentation tanks have been successfully industrialized [4]. Industrial Cluster Development - Regions like Beijing and Tianjin have emerged as innovation hubs for bio-manufacturing, while provinces such as Shandong, Heilongjiang, and Henan have developed into major manufacturing bases for bulk bio-fermentation products [5]. - The "14th Five-Year Plan" has fostered the growth of numerous backbone enterprises with annual revenues exceeding 10 billion yuan, along with the emergence of several national-level manufacturing champions and specialized "little giant" enterprises [5]. Policy and Recognition - The Ministry of Industry and Information Technology (MIIT) has released a list of 35 landmark bio-manufacturing products, with companies like New Hope Liuhe, Blue Crystal Microbiology, and Huaxi Biological among the applicants [6][8].